Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Serum albumin, ferritin, folate, vitamin B12, and 25-hydroxyvitamin D levels remained stable relative to baseline, with no significant differences between groups.
Source: Postoperative complications. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cohort study.
Cohort study
Examines exposures and outcomes over time within a defined group.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
In this retrospective cohort study, 26 patients with mild obesity and 76 matched patients with higher BMI underwent MBS between 2013 and 2020.
Source: Abstract.
After surgery, patients were managed within a structured multidisciplinary program involving metabolic and bariatric surgeons, endocrinologists, dietitians, rehabilitation physicians, and specialized metabolic and bariatric nurses.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Metabolic and bariatric surgery in mild obesity: mid-term outcomes and safety in an Asian population
Cohort study · Frontiers in Endocrinology · 2026
Original publication title
Metabolic and bariatric surgery in mild obesity: mid-term outcomes and safety in an Asian population
Copyright © 2026 Zhong, Chen, Huang, Zhu, Tang, Ouyang, Chu and Feng.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
To evaluate the mid-term (≥3 years) efficacy and safety of MBS in Asian patients with mild obesity, compared with those with BMI ≥MIhe kg/m².
Source: ObjectiveAbstract: What methods does the paper describe?
In this retrospective cohort study, 26 patients with mild obesity and 76 matched patients with higher BMI underwent MBS between 2013 and 2020. Outcomes included percent total weight loss (%TWL), metabolic control, remission of obesity-related comorbidities, and postoperative complications. The primary composite endpoint was defined as glycated hemoglobin <6.5%, low-density lipoprotein cholesterol <2.6 mmol/L, systolic blood pressure <130 mmHg, and homeostasis model assessment of insulin resistance <2.5 mmol/L, μU/mL.
Source: MethodsAbstract: Results
At a mean follow-up of approximately 5 years, the mild obesity group achieved lower %TWL than the higher-BMI group (approximately 20% vs 26%, P < 0.05). Despite this, the rate of achieving the composite metabolic endpoint was comparable (30.7% vs 27.6%, P = 0.76). Both groups demonstrated sustained improvements in glycemic control, lipid profile, blood pressure, and insulin resistance. Remission of type 2 diabetes, hypertension, hyperuricemia, and metabolic-associated fatty liver disease increased significantly in both groups (all P < 0.05).
Notably, a substantially greater proportion of patients in the obesity group achieved normalization of body weight (BMI <24 kg/m²). Complication rates were low and comparable.
Source: ResultsAbstract: Conclusion
In Asian patients, MBS appears safe and provides durable metabolic benefits across BMI categories. Despite losing less weight, those with mild obesity achieved similar cardiometabolic improvements and were more likely to reach a normal BMI. These findings are preliminary. Future research should prioritize large, multicenter studies focusing on the BMI 27.5 to 30 kg/m² subgroup without advanced metabolic disease, randomized trials comparing surgery with current pharmacotherapies, and long-term studies tracking hard cardiovascular endpoints.
Source: ConclusionAuthors’ abstract
Background
Metabolic and bariatric surgery (MBS) is an established treatment for severe obesity, but its role in Asian patients with mild obesity (body mass index [BMI] 27.5-32.5 kg/m²) remains controversial due to limited mid-term evidence. This study evaluated the ≥3-year outcomes of MBS in this population compared with patients with BMI ≥32.5 kg/m².
Objective
To evaluate the mid-term (≥3 years) efficacy and safety of MBS in Asian patients with mild obesity, compared with those with BMI ≥MIhe kg/m².
Methods
In this retrospective cohort study, 26 patients with mild obesity and 76 matched patients with higher BMI underwent MBS between 2013 and 2020. Outcomes included percent total weight loss (%TWL), metabolic control, remission of obesity-related comorbidities, and postoperative complications. The primary composite endpoint was defined as glycated hemoglobin <6.5%, low-density lipoprotein cholesterol <2.6 mmol/L, systolic blood pressure <130 mmHg, and homeostasis model assessment of insulin resistance <2.5 mmol/L, μU/mL.
Results
At a mean follow-up of approximately 5 years, the mild obesity group achieved lower %TWL than the higher-BMI group (approximately 20% vs 26%, P < 0.05). Despite this, the rate of achieving the composite metabolic endpoint was comparable (30.7% vs 27.6%, P = 0.76). Both groups demonstrated sustained improvements in glycemic control, lipid profile, blood pressure, and insulin resistance. Remission of type 2 diabetes, hypertension, hyperuricemia, and metabolic-associated fatty liver disease increased significantly in both groups (all P < 0.05).
Notably, a substantially greater proportion of patients in the obesity group achieved normalization of body weight (BMI <24 kg/m²). Complication rates were low and comparable.
Conclusion
In Asian patients, MBS appears safe and provides durable metabolic benefits across BMI categories. Despite losing less weight, those with mild obesity achieved similar cardiometabolic improvements and were more likely to reach a normal BMI. These findings are preliminary. Future research should prioritize large, multicenter studies focusing on the BMI 27.5 to 30 kg/m² subgroup without advanced metabolic disease, randomized trials comparing surgery with current pharmacotherapies, and long-term studies tracking hard cardiovascular endpoints.
Publication and source details
Original title: Metabolic and bariatric surgery in mild obesity: mid-term outcomes and safety in an Asian population
Wanying Zhong; Lijun Chen; Yuanhao Huang; Dalong Zhu; Wenjuan Tang; Yuqin Ouyang; Xuehui Chu; Wenhuan Feng
Frontiers in Endocrinology · 2026
* Correspondence: Wenhuan Feng, fengwh501@163.com; Xuehui Chu, chuxuehui@njglyy.com†These authors have contributed equally to this work
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T22:29:22.352370+00:00
DOI: 10.3389/fendo.2026.1828283 · PMC13229718